Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 277

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 277
---
 of December 31, 2024 contains approximately 27 issued and unexpired U.S.
patents and nine pending U.S. patent applications. Our portfolio also includes certain foreign counterparts of these patents and patent applications including Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan, Korea, Mexico, New
Zealand, South Africa, Taiwan, and certain countries within the European Patent Convention.

With respect to ZTlido and SP-103, our patents and patent applications cover compositions and methods of treatment. We license eight issued U.S. patents and two pending U.S. patent applications relating to lidocaine topical system
compositions and methods of treating pain with lidocaine topical system compositions. The patents are U.S. Pat. Nos. 9,283,174, 9,925,264, 9,931,403, 10,765,749, 10,765,640, 11,278,623, 11,786,455, and 11,793,766, all of which expire in 2031.

With respect to GLOPERBA, our licensed patents include U.S. Pat. Nos. 9,907,751, 10,226,423, 10,383,820, 10,383,821, and 11,672,759, which
relate to liquid colchicine formulations for oral administration and associated methods of use. U.S. Pat. No. 10,226,423 expires in 2037. The remaining patents related to GLOPERBA expire in 2036.

With respect to ELYXYB, our patents and patent applications relate to liquid oral celecoxib formulations and associated methods of use. The
issued patents include U.S. Pat. Nos. 9,572,819, 9,795,620, 9,949,990, 10,376,527, 10,799,517, 10,722,456, and 12,168,000. U.S. Pat. No. 12,168,000 expires in 2041. The remaining patents related to ELYXYB expire in 2036.

With respect to our product candidate SEMDEXA, our patents and patent applications that we own include formulations and methods of treatment.
The patents are U.S. Pat. Nos. 10,500,284, 10,117,938, and 11,020,485, all